TRIAMTERENE Drug Patent Profile
✉ Email this page to a colleague
When do Triamterene patents expire, and what generic alternatives are available?
Triamterene is a drug marketed by Agnitio, Hibrow Hlthcare, Ani Pharms, Cadila, Chartwell Rx, Duramed Pharms Barr, Lannett Co Inc, Norvium Bioscience, Novartis, Sandoz, Vitarine, Am Therap, Apotex Inc, Pliva, Quantum Pharmics, Rubicon, Watson Labs, and Zydus Pharms. and is included in twenty-four NDAs.
The generic ingredient in TRIAMTERENE is hydrochlorothiazide; triamterene. There are thirty-two drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRIAMTERENE?
- What are the global sales for TRIAMTERENE?
- What is Average Wholesale Price for TRIAMTERENE?
Summary for TRIAMTERENE
| US Patents: | 0 |
| Applicants: | 18 |
| NDAs: | 24 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 130 |
| Clinical Trials: | 8 |
| Patent Applications: | 4,212 |
| Drug Prices: | Drug price information for TRIAMTERENE |
| Drug Sales Revenues: | Drug sales revenues for TRIAMTERENE |
| What excipients (inactive ingredients) are in TRIAMTERENE? | TRIAMTERENE excipients list |
| DailyMed Link: | TRIAMTERENE at DailyMed |
Recent Clinical Trials for TRIAMTERENE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, Irvine | Phase 4 |
| Vanderbilt University | Phase 4 |
| West China Hospital | Phase 4 |
Pharmacology for TRIAMTERENE
| Drug Class | Potassium-sparing Diuretic |
| Physiological Effect | Decreased Renal K+ Excretion Increased Diuresis |
Medical Subject Heading (MeSH) Categories for TRIAMTERENE
Anatomical Therapeutic Chemical (ATC) Classes for TRIAMTERENE
US Patents and Regulatory Information for TRIAMTERENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Pharms | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 208360-001 | Jun 29, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 208360-002 | Jun 29, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Agnitio | TRIAMTERENE | triamterene | CAPSULE;ORAL | 211581-001 | Aug 19, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
